国际循环网版权所有，谢绝任何形式转载，侵犯版权者必予法律追究。

<Internaitonal Circulation>: In your presentation， you mentioned the EPITHET trial， which showed that there is no significant difference in the primary outcome， but it has a trend. The secondary endpoint shows statistical significance. What are the possible reasons for the non-significance of the primary outcome? Do you think the result of EPITHET trial has enough power to change the current therapeutic window for intravenous thrombolysis? 《国际循环》：您在演讲时提到了EPITHET试验，其主要临床结果有差异，但差异无显著性，次级终点有显著差异。您认为主要终点没有显著差异的可能原因是什么？您认为EPITHET试验的结果是否会改变静脉溶栓的治疗窗？